WYETH LLCLetter Agreement • August 14th, 2020 • Aptevo Therapeutics Inc. • Pharmaceutical preparations
This letter agreement (the "Letter Agreement") constitutes Amendment No. 3 to the Agreement referred to above. Capitalized terms used but not defined herein shall have the meanings set forth in the Agreement. EPDS and Wyeth desire to amend the Agreement with respect to the restrictions on Development and Commercialization of CD20 Antigens and CD20 Products. This Letter Agreement sets forth the agreement of EPDS and Wyeth with respect to such amendment.
WYETH LLC ACTING THROUGH ITS WYETH PHARMACEUTICALS DIVISION COLLEGEVILLE, PENNSYLVANIA 19426 USALetter Agreement • August 14th, 2020 • Aptevo Therapeutics Inc. • Pharmaceutical preparations
This letter agreement (the "Letter Agreement") constitutes Amendment No. 2 to the Agreement referred to above. Capitalized terms used but not defined herein shall have the meanings set forth in the Agreement. Trubion and Wyeth desire to discontinue their collaborative efforts toward the research and Development of [*] and, as a result thereof, wish to amend the Agreement as set forth herein. In addition, Trubion and Wyeth desire to discontinue their collaborative efforts towards the research and Development of the following Wyeth Targets: [*] (the "Discontinued Targets"), of SMIPs directed against such Discontinued Targets (the "Discontinued SMIPs") and of Other Products containing SMIPS directed against such Discontinued Targets (the "Discontinued Other Products"). This Letter Agreement sets forth the agreement of Trubion and Wyeth with respect to such amendment.
Dr Mary Collins CSO/VP Immunology & Autoimmunity Pfizer Inc 200 Cambridge Park Drive Cambridge, MA 02140Letter Agreement • August 14th, 2020 • Aptevo Therapeutics Inc. • Pharmaceutical preparations
COLLABORATION AND LICENSE AGREEMENT by and between WYETH acting through its Wyeth Pharmaceuticals Division and TRUBION PHARMACEUTICALS, INC. December 19, 2005Collaboration and License Agreement • August 14th, 2020 • Aptevo Therapeutics Inc. • Pharmaceutical preparations • New York
This Collaboration and License Agreement (the “Agreement”) is entered into as of December 19, 2005 (the “Signing Date”), by and between Wyeth, together with its Affiliates (as defined below), acting through its Wyeth Pharmaceuticals Division, a corporation organized and existing under the laws of the State of Delaware and having a place of business at 500 Arcola Road, Collegeville, Pennsylvania 19426 (collectively, “Wyeth”) and Trubion Pharmaceuticals, Inc., together with its Affiliates (as defined below), a corporation organized and existing under the laws of the State of Delaware and having a principal place of business at 2401 4th Avenue, Suite 1050, Seattle, Washington 98121 (collectively, “Trubion”). Wyeth and Trubion may each be referred to herein individually as a “Party” and collectively as the “Parties”.
